Technical Analysis for THRX - Theseus Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Volume Surge | Other | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Bollinger Band Squeeze | Range Contraction | -0.25% | |
Narrow Range Bar | Range Contraction | -0.25% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Shooting Star Candlestick | Bearish | -0.49% |
Get a Trading Sidekick!
- Earnings date: 11/20/2023
Theseus Pharmaceuticals, Inc. Description
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Organic Compounds Chemical Compounds Non Small Cell Lung Cancer Lung Cancer Protein Kinase Inhibitor Targeted Therapy Epidermal Growth Factor Receptor Tyrosine Kinase Non Small Cell Lung Carcinoma Advanced Gastrointestinal Stromal Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.37 |
52 Week Low | 2.05 |
Average Volume | 462,242 |
200-Day Moving Average | 4.97 |
50-Day Moving Average | 3.96 |
20-Day Moving Average | 4.04 |
10-Day Moving Average | 4.07 |
Average True Range | 0.05 |
RSI (14) | 59.84 |
ADX | 37.46 |
+DI | 26.07 |
-DI | 12.23 |
Chandelier Exit (Long, 3 ATRs) | 3.97 |
Chandelier Exit (Short, 3 ATRs) | 4.12 |
Upper Bollinger Bands | 4.11 |
Lower Bollinger Band | 3.97 |
Percent B (%b) | 0.66 |
BandWidth | 3.35 |
MACD Line | 0.04 |
MACD Signal Line | 0.06 |
MACD Histogram | -0.0107 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.08 | ||||
Resistance 3 (R3) | 4.08 | 4.07 | 4.07 | ||
Resistance 2 (R2) | 4.07 | 4.07 | 4.07 | 4.07 | |
Resistance 1 (R1) | 4.07 | 4.07 | 4.07 | 4.07 | 4.07 |
Pivot Point | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 |
Support 1 (S1) | 4.06 | 4.06 | 4.06 | 4.06 | 4.05 |
Support 2 (S2) | 4.05 | 4.06 | 4.05 | 4.05 | |
Support 3 (S3) | 4.05 | 4.05 | 4.05 | ||
Support 4 (S4) | 4.05 |